|
|
| News & Events |
| High-Throughput Absorption Depth Profiling in Stratum Corneum for Topical and Transdermal Formulation Development |
08-11-2011 |
Zyleris PharmaTech (www.Zyleris.com) has announced the launch of a new topical formulation development service: high-throughput absorption depth profiling in stratum corneum (SC) layer for topical and transdermal formulation development.
The service combines Zyleris’ high-throughput Franz Cell formulation screening (HTS) platform and high-speed tape-stripping technique. Each HTS system consists of a compact 108-cell screening station with flexibility for both absorption and penetration studies. The system is fully validated against industry-standard Franz Cell technology. Our high-speed tape-stripping technique is able to process 48 tape strips at a time, which offers consistency and uniformity across all strips during each stripping cycle.
SC layer is the rate-limiting barrier for skin absorption and permeation. Tape-stripping technique is a standard method in studying kinetics and depth profiling of the absorption and permeation process. Current Franz Cell technology and standard tape-stripping technique is a slow and tedious process, thus the market is ripe for a high speed, yet cost efficient solution. The combination of Zyleris’ first-in-class HTS technology and high-speed tape-stripping technique fills this gap. It will allow researchers to rapidly screen drug release profiles in SC layer from topical formulations. The release profiling study is particularly critical for development of drugs that target SC layer, such as antifungals and keratolytics.
Zyleris’ objective is to continue developing innovative solutions, technologies, and services for topical and transdermal drug research and development.
About Zyleris PharmaTech
Founded in 2009 and headquartered in Chicago, IL, U.S.A, Zyleris PharmaTech is a contract research service company delivering best-in-class high-throughput experimentation technologies and services for accelerating topical and transdermal drug R&D process. For more information about the company, please visit us at www.zyleris.com. |
|
| High-Throughput Formulation Screening Service for Topical and Transdermal Drug Development |
07-26-2010 |
Zyleris PharmaTech (www.Zyleris.com) has announced the launch of its high-throughput formulation screening service for topical and transdermal drug development based on the company’s innovative experimentation technology.
Zyleris’ technology is designed to transform topical and transdermal drug development. The technology utilizes Franz Cell principle in a high-throughput fashion, which is at least 20x faster than present industrial standard Franz Cell technology and lowering costs up to 90% per formulation. It also offers higher detection sensitivity than Franz Cell technology due to its unique design. The main technical features include easy-to-use compact design, flexible diffusion area suitable for percutaneous absorption and permeation studies, all glass and Teflon construction, and an easy sample collection mechanism.
"Many researchers tell us that identifying suitable topical and transdermal formulations for clinical development is often quite tedious and expensive. Due to the limitations of current Franz Cell technology, such as low speed and high cost, only a limited number of candidate formulations can reasonably be screened and evaluated. Researchers always wonder: is the formulation slated for clinical development really best possible one to move forward? Thus, the market is ripe for a high speed and yet cost efficient solution. Our technology fills this gap by offering the best of both worlds - speed associated with high-throughput technology and yet result compatibility with industrial standard Franz Cell technology. We understood that from the beginning and developed a truly innovative solution for this challenge and brought speed and cost efficiency to the process." says Zyleris founder and CEO, Jerry Zhang, PhD.
Zyleris’ objective is to continue developing innovative solutions, technologies, and services for topical and transdermal drug research and development.
About Zyleris PharmaTech
Founded in 2009 and headquartered in Chicago, IL, U.S.A, Zyleris PharmaTech is a contract research service company delivering best-in-class high-throughput experimentation technologies and services for accelerating topical and transdermal drug R&D process. For more information about the company, visit www.zyleris.com.
Contact Information
Jerry Zhang
Phone: 847-604-8474
Email: jerryzhang@zyleris.com
### |
|
| High-Throughput Screening of Compound Library for Topical and Transdermal Delivery |
04-27-2011 |
Zyleris PharmaTech (www.Zyleris.com) has announced the launch of a new drug development service: high-throughput screening of compound library to identify drug candidates for topical and transdermal delivery.
The screening service utilizes Zyleris’ Franz Cell-based high-throughput technology. Each screening system consists of a compact 108-cell screening station with flexibility for both absorption and penetration studies. The system is fully validated against industry-standard Franz Cell technology. It can be used with any human or animal tissue including skin, buccal, lung, ocular, nail (with adapter) or synthetic membrane.
For many local and system indications, topical and transdermal delivery is a valuable and often preferred option in the drug development process. However, current Franz Cell technology is ill-equipped for screening of compound library. The market is ripe for a high speed and yet cost efficient solution. Our system fills this gap. It will allow researchers to rapidly screen compound library and make informed, go/no-go decision with respect to the delivery route.
Zyleris’ objective is to continue developing innovative solutions, technologies, and services for topical and transdermal drug research and development.
About Zyleris PharmaTech
Founded in 2009 and headquartered in Chicago, IL, U.S.A, Zyleris PharmaTech is a contract research service company delivering best-in-class high-throughput experimentation technologies and services for accelerating topical and transdermal drug R&D process. For more information about the company, please visit us at www.zyleris.com. |
|
|
|
| |
| |
| |
|
